Interpace Announces Acceptance of Seminal Clinical Validation Study for Thyroid Assays
Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting
PARSIPPANY, NJ, July 21, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that a peer-reviewed manuscript describing results from a seminal clinical validation
study of the combination of ThyGeNEXT and ThyraMIR has been accepted for publication in the highly respected journal, Diagnostic Cytopathology. The study, led by Dr. Mark Lupo from the
Thyroid and Endocrine Center of Florida, reported on the ability of the combination of ThyGeNEXT/ThyraMIR tests to successfully stratify nearly 200 indeterminate thyroid nodules for risk of
malignancy. Sites participating in this multicentered study included Cedars-Sinai Medical Center, Jackson Thyroid & Endocrine Clinic, University of Michigan, Massachusetts General
Hospital/Harvard Medical School, and the University of Arkansas for Medical Sciences.
According to Jack Stover, President and CEO of Interpace, “We’re excited that this important study will soon be published in such a prominent peer reviewed journal and will be further highlighted
at the ASC Annual Meeting in November.” He continued “We look forward to sharing these results with the physician and payer communities shortly.”
About ThyGeNEXT and ThyraMIR
ThyGeNEXT is Interpace’s most recent next generation sequencing test that was expanded from its original version (ThyGenX) to include markers that have targeted therapies and those that can identify aggressive forms of thyroid cancer.
Lesen Sie auch
ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGeNEXT and ThyraMIR are covered by Medicare and Commercial insurers, with more than 280 million members covered.